NCT07235046

A Study of DII235 in Adults With Elevated Lipoprotein(a)

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of DII235 in Adults With Elevated Lipoprotein(a)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to determine the safety and efficacy of DII235 in adults with elevated lipoprotein(a).

Conditions

• Lipoprotein Disorder

Interventions

Type	Name	Description
DRUG	DII235	Solution for injection
DRUG	Saline	solution for injection

Timeline

• Start date: 2025-12-02
• Primary completion: 2027-09-08
• Completion: 2028-09-08
• First posted: 2025-11-19
• Last updated: 2026-04-14

Locations

66 sites across 4 countries: United States, China, Germany, Japan

Regulatory

• FDA-regulated drug study